Cormedix Inc. (CRMD) Stock Price & Analysis
Cormedix Inc. (CRMD) rose 1.29% to USD 8.65 as of June 10, 2026 at 00:26 UTC, according to Nexqual real-time market data.
CRMD last closed at USD 8.54; the session ranged USD 8.46–8.83 on volume of 1,381,335 shares. Market capitalization is $678.61M, with a 52-week range of USD 6.13–17.43 (NGM). Source: Nexqual, June 10, 2026 at 00:26 UTC.
Key Statistics (as of June 10, 2026 at 00:26 UTC)
| Price | USD 8.65 |
|---|---|
| Change | ▲ 1.29% (up) |
| Previous Close | USD 8.54 |
| Open | USD 8.61 |
| Day Range | USD 8.46 – 8.83 |
| 52-Week Range | USD 6.13 – 17.43 |
| Volume | 1,381,335 shares |
| Market Cap | $678.61M |
| Exchange | NGM |
Technical Analysis (CRMD)
Nexqual's technical model rates CRMD "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.14 (neutral) |
| vs SMA50 | Above (USD 7.7) |
| MACD | 0.24 (positive) |
Analyst Ratings (CRMD)
Wall Street analysts rate CRMD "None" based on 6 analysts, with a mean price target of USD 15.33 (range USD 13–19), per Nexqual as of June 10, 2026 at 00:26 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 15.33 |
| High Target | USD 19 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (CRMD)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.27 |
| Revenue Estimate | $94.95M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.35 vs est 0.33 ▲ beat |
| 2025-12-31 | USD 0.16 vs est 0.81 ▼ miss |
| 2025-09-30 | USD 1.41 vs est 0.63 ▲ beat |
| 2025-06-30 | USD 0.28 vs est 0.19 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
Financials & Fundamentals (CRMD)
| Total Revenue | $400.05M |
|---|---|
| Revenue Growth (YoY) | +226.10% |
| Gross Margin | +91.86% |
| Operating Margin | +49.96% |
| Profit Margin | +45.25% |
| ROE | +65.59% |
| Debt / Equity | 33.73 |
| Current Ratio | 2.98 |
| Total Cash | $178.09M |
| Total Debt | $147.42M |
| Free Cash Flow | $119.84M |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
Financial Health Score (CRMD)
Nexqual rates Cormedix Inc.'s overall financial health "Strong" across five dimensions, as of June 10, 2026 at 00:26 UTC.
| Growth | Strong — Revenue +617% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 92%, operating 50% |
| Balance Sheet | Strong — $178M cash vs $147M debt, net cash position |
| Cash Flow | Strong — FCF $120M, 38% margin |
| Efficiency | Strong — ROE 66%, ROA 26.4% |
Ownership (CRMD)
| Insider Ownership | +7.51% |
|---|---|
| Institutional Ownership | +54.50% |
| Shares Outstanding | 78.45M |
| Float | 66.55M |
| Short % of Float | +20.07% |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
Leadership (CRMD)
Cormedix Inc. is led by Joseph Todisco (age 49), CEO & Chairman of the Board of Directors, per Nexqual as of June 10, 2026 at 00:26 UTC.
| CEO & Chairman of the Board of Directors | Joseph Todisco (age 49) |
|---|---|
| Executive VP, Chief Operating Officer & Chief Integration Officer | Elizabeth Masson-Hurlburt B.A. (age 46) |
| EVP & Chief Financial Officer | Susan Blum (age 52) |
| Senior Vice President of Market Access | Peter Sullivan BCOP, Pharm.D. |
Major Backers & Investors (CRMD)
Notable institutional backers of Cormedix Inc. include Deep Track Capital, Lp, Royce & Associates LP, UBS Group AG, according to Nexqual as of June 10, 2026 at 00:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 8% |
| Royce & Associates LP | 2.41% |
| UBS Group AG | 1.96% |
| Oberweis Asset Management Inc. | 1.54% |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.48% |
| ROYCE FUND-Royce Small-Cap Fund | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.66% |
| Vanguard Group | 8.84% |
| State Street | 3.55% |
| Geode Capital | 2.32% |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
From Cormedix Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
- Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
- CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TLPH | Talphera, Inc. | USD 0.82 | ▲ 4.56% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| OGEN | Oragenics Inc. | USD 0.6 | ▲ 1.69% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| CAPR | Capricor Therapeutics, Inc. | USD 26.01 | ▼ 2.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:26 UTC. This page is informational and not investment advice.